The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The significance of minimal residual disease (MRD) in relapsed childhood B-lymphoblastic leukemia (B-ALL): A report from Children’s Oncology Group (COG) protocol AALL0433.
Glen Lew
No relevant relationships to disclose
Xiaomin Lu
No relevant relationships to disclose
Rochelle Yanofsky
No relevant relationships to disclose
Susan R. Rheingold
No relevant relationships to disclose
James Whitlock
No relevant relationships to disclose
Scott D Gulig
No relevant relationships to disclose
Meenakshi Devidas
No relevant relationships to disclose
Michael Pulsipher
No relevant relationships to disclose
Caroline Aimee Hastings
No relevant relationships to disclose
Naomi Joan Winick
No relevant relationships to disclose
William L. Carroll
No relevant relationships to disclose
Michael J. Borowitz
Research Funding - Amgen; Becton-Dickinson; Bristol-Myers Squibb; Genzyme; MedImmune
Stephen Hunger
No relevant relationships to disclose